Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:5:1469-73.
doi: 10.2147/OPTH.S25636. Epub 2011 Oct 12.

Comparison of selective laser trabeculoplasty (SLT) in primary open angle glaucoma and pseudoexfoliation glaucoma

Marcelo Ayala  1 , Enping Chen
Affiliations

Comparison of selective laser trabeculoplasty (SLT) in primary open angle glaucoma and pseudoexfoliation glaucoma

Marcelo Ayala et al. Clin Ophthalmol. 2011.

Abstract

Background and objective: The aim of the present study was to compare intraocular pressure (IOP) reduction and inflammation after selective laser trabeculoplasty (SLT) treatment in patients suffering from primary open angle (POAG) vs pseudoexfoliative (PXFG) glaucoma.

Study design/patients and methods: Sixty patients (60 eyes) participated in the study. Glaucoma patients (POAG or PXFG) scheduled for treatment with SLT were included. Inflammation was measured with a laser flare meter (Kowa FM-500). Measurements were made before SLT and 2 hours, 1 week, and 1 month after SLT treatment. IOP was also checked at the same time intervals.

Results: Inflammation after SLT showed no significant difference between the groups (t-test, before: P = 0.16; 2 hours: P = 0.14; 1 week: P = 0.12; and 1 month: P = 0.36). IOP reduction was the same in both groups (t-test, P = 0.27).

Conclusion: SLT safely reduces IOP in both POAG and PXFG. Pseudoexfoliation does not seem to be a risk factor for post-laser complications.

Keywords: glaucoma; inflammation; intraocular pressure; laser; pseudoexfoliation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intraocular pressure reduction comparing before and 1 month after SLT treatment, the bars represent 95% confidence interval for the mean. Notes: t-test, P = 0.27.
Figure 2
Figure 2
Flare measurements in both groups at different time intervals after SLT treatment. Notes: The bars represent 95% confidence intervals for the mean. (▴) represents the mean for the prostaglandin analogs group. (■) represents the mean for the non-prostaglandin analogs group. (t-test, before: P = 0.16; 2 hours: P = 0.14; 1 week: P = 0.12, and 1 month: P = 0.36).
See this image and copyright information in PMC

References

    1. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56. - PubMed
    1. The Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT). Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology. 1990;97(11):1403–1413. - PubMed
    1. The Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol. 1995;120(6):718–731. - PubMed
    1. Lee R, Hutnik CM. Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan. Can J Ophthalmol. 2006;41(4):449–456. - PubMed
    1. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995;60(4):359–371. - PubMed